A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00363610
Recruitment Status : Terminated (No recommended Phase II dose was determined.)
First Posted : August 15, 2006
Last Update Posted : May 20, 2008
Information provided by:
Enzon Pharmaceuticals, Inc.

Brief Summary:
This study will research the side effects of pegaspargase (pronounced "peg-as-par-gase"); its brand name is ONCASPAR® when it is used with another FDA-approved cancer treatment (chemotherapy) drug called gemcitabine HCl (pronounced "gem-site-a-bean"; its brand name is GEMZAR®.

Condition or disease Intervention/treatment Phase
Tumors Lymphoma Drug: Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma Phase 1

Detailed Description:

The purpose of this research study is for the study's sponsor, Enzon Pharmaceuticals, Inc. ("Enzon"), to learn more about its drug pegaspargase. Pegaspargase is the drug's scientific or generic name. Because it is already approved by the Food and Drug Administration (FDA), it also has a brand name - ONCASPAR®. It is approved by the FDA for the treatment of a type of leukemia (cancer of white blood cells). However, pegaspargase is not approved by the FDA for treatment of the cancer in this study. This study will research the side effects of pegaspargase when it is used with another FDA-approved cancer treatment (chemotherapy) drug called gemcitabine HCl; its brand name is GEMZAR®. It is approved for the treatment of patients with cancer of the pancreas and of patients with breast cancer. However, gemcitabine is not approved by the FDA for treatment of any other types of cancer.

In addition, the combination of pegaspargase and gemcitabine for solid tumors and lymphoma in this study is investigational. This type of study treatment is called a "combination treatment" or a "combination study." The information (research data) from this study will be used by Enzon to plan other "combination" research studies with pegaspargase plus gemcitabine for the treatment of certain cancers.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of Intravenous Pegaspargase in Combination With Intravenous Gemcitabine HCl in the Treatment of Advanced and/or Metastatic Solid Tumors and Lymphoma
Study Start Date : July 2006
Actual Primary Completion Date : November 2007
Estimated Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Primary Outcome Measures :
  1. The primary objectives of this Phase 1 study of pegaspargase in combination with gemcitabine are to determine the maximum tolerated dose of IV pegaspargase when administered with gemcitabine
  2. and to determine the recommended Phase 2 dose of pegaspargase

Secondary Outcome Measures :
  1. The secondary objectives of this study are to evaluate the safety and tolerability of the combination study treatment
  2. to determine the PD/PK profile and immunogenicity of pegaspargase
  3. to determine the PK profile of gemcitabine when administered in combination with pegaspargase
  4. and to detect preliminary evidence of tumor

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Capable of understanding the protocol requirements and risks and providing written informed consent.
  • Histologically or cytologically confirmed diagnosis of advanced and/or metastatic solid tumor or lymphoma (Hodgkin's or non-Hodgkin's), and have either failed primary treatment or there is no available standard treatment.
  • Prior standard therapy was not effective, or no known therapy will extend survival or provide benefit.
  • Measurable or evaluable disease.
  • Age 18 years or older.
  • Score of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale.
  • Absolute neutrophil count (ANC)≥ 1500/μL.
  • Platelet count ≥ 100,000/μL.
  • Hemoglobin ≥ 9.0 g/dL.
  • Fibrinogen ≥ 0.75x the lower limit of normal (LLN), and PT, PTT, and INR ≤ 1.5x the upper limit of normal (ULN).
  • Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min.
  • Total bilirubin ≤ 1.5 mg/dL.
  • Transaminases (AST, ALT) ≤ 2.5x the upper limit of normal (ULN) (may be ≤ 5.0x ULN if due to metastatic disease in the liver).
  • Amylase and lipase levels are within normal limits.

Any subject who has given informed consent to participate in the clinical study and who meets all entry criteria for the study may participate in the tumor analysis part of the study.

Exclusion Criteria:

  • Subjects meeting any of the following exclusion criteria will not be eligible for enrollment.
  • Concurrent serious medical illness that could potentially interfere with protocol compliance.
  • Has pancreatitis or a history of pancreatitis, not related to pancreatic cancer.
  • Has a coagulopathy or a history of coagulopathy.
  • Known chronic infectious disease, such as AIDS or hepatitis (screening for hepatitis and HIV will not be performed).
  • Positive screening pregnancy test or is breast-feeding.
  • Female or male subject of reproductive capacity unwilling to use methods appropriate to prevent pregnancy during the course of this protocol.
  • Known or clinically suspected active brain metastases.
  • Received pegaspargase (Oncaspar®, PEG-L-asparaginase) or any asparaginase or asparaginase-containing drug, at any time prior to this study.
  • Received prior chemotherapy, immunotherapy or an investigational agent regimen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00363610

United States, Arizona
TGen Clinical Research Services at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198-8511
United States, Texas
Cancer Therapy & Research Center, Institute for Drug Development
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Enzon Pharmaceuticals, Inc.

Responsible Party: Enzon Pharmaceuticals, Inc. Identifier: NCT00363610     History of Changes
Other Study ID Numbers: EZ-002-001
First Posted: August 15, 2006    Key Record Dates
Last Update Posted: May 20, 2008
Last Verified: May 2008

Keywords provided by Enzon Pharmaceuticals, Inc.:
Advanced and/or Metastatic Solid Tumors and Lymphoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs